Athira Pharma presents data on potential benefit of ATH-1105 for ALS at NEALS

Athira Pharma presented new preclinical data supporting the potential benefit of ATH-1105 for the treatment of amyotrophic lateral sclerosis, ALS, at the 22nd Annual Northeast ALS Consortium or NEALS Meeting, taking place October 4-6 virtually and in-person in Clearwater, Florida. ATH-1105 is an orally administered small molecule therapeutic candidate designed to enhance the neurotrophic hepatocyte growth factor HG system.”Our findings add to the growing body of evidence that ATH-1105 offers broad neuroprotective activity in preclinical models of ALS, including the rescue of motor neurons from insults in vitro and reduction in plasma neurofilament light NfL , decreased pTDP-43 accumulation in nerves, and improvements in motor and nerve function in vivo,” stated Kevin Church, Ph.D., Chief Scientific Officer, Athira Pharma. “There is an urgent need for new ALS treatment options, particularly those aimed at stopping or slowing neurodegeneration. We are encouraged by the consistent benefit of ATH-1105 in these animal models, whether given pre- or post-symptom onset or in combination with riluzole. These findings underscore the broad neuroprotective activity of ATH-1105 and support its ongoing development.”